- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05428774
Efficacy of Different Oral Rehydration Solutions on the Hydration Status of Healthy Males
January 23, 2023 updated by: Liquid I.V.
Dehydration lowers both physical and mental performance if it is severe enough.
Performance declines are more pronounced in hot conditions or after prolonged strenuous activity such as exercise.
Most individuals drink less than their sweat losses during activity, while some individuals overdrink and develop a sodium deficiency.
Water and electrolyte balance must be restored as part of the recovery process after any activity that causes sweating.
Plain water causes a decrease in plasma sodium concentration and osmolality, which reduces the desire to drink and increases urine production.
Unless the volume ingested exceeds the loss, individuals are in net negative fluid balance throughout the recovery period due to urinary losses.
When sodium and potassium are added to rehydration fluids, urine production is reduced in the hours following rehydration.
Rehydration is only possible if a volume of fluid equal to or greater than the amount lost through sweat is consumed, together with adequate electrolytes.
The two test products for this study, are novel hydration beverage formulas.
They are an electrolyte drink mixture with five essential vitamins and three times more electrolytes than typical sports beverages.
The test products create an osmotic force that permits water to be supplied to the bloodstream sooner in the digestive system by using a specific ratio of sodium, glucose, and potassium.
This randomized, placebo-controlled, semi-blind, crossover study will evaluate the effects of the test products on rehydration in healthy adults.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
15
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37204
- Lipscomb University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 35 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy males 18-35 years old at the time of screening. Participants need to be competent i.e., able to understand what is to take place and able to provide a free decision on agreeing to the activity/taking part in the study. Participants must be able to read and understand study instructions and any other relevant study documents. Willing to following the lifestyle and dietary restrictions as detailed in the Information Sheet for study.
Exclusion Criteria:
- A history or presence of a clinically relevant cardiac, renal, hepatic, endocrine (including diabetes mellitus), pulmonary, biliary, gastrointestinal, pancreatic, or neurologic disorder. Consumption other nutritional supplements, performance enhancing drugs, and non-steroidal anti-inflammatory drugs (NSAIDs) during the clinical. Participant has any medical condition which alters fluid balance in the body as confirmed by a health history questionnaire. Following a dietary pattern which may alter our findings (e.g., low carbohydrate/ketogenic diet, carnivore diet, intermittent fasting etc.). Women are excluded due to the variability of fluid retention during the menstrual cycle. Participant is not currently enrolled in another clinical study. Participant is consuming any medication which may alter fluid retention such as diuretics. The participant is an employee of the Sponsor.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Test Product 1
Participants will consume test product 1 during one experimental visit.
|
Participants will receive TP1 during one experimental visit.
|
|
Experimental: Test Product 2
Participants will consume test product 2 during one experimental visit.
|
Participants will receive TP2 during one experimental visit.
|
|
Placebo Comparator: Placebo
Participants will consume placebo during one experimental visit.
|
Participants will receive placebo during one experimental visit.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Beverage hydration index
Time Frame: Through study completion, average of 6 weeks
|
The primary objective of this study is to investigate the efficacy of two different oral rehydration solutions on the hydration status in healthy males via the beverage hydration index
|
Through study completion, average of 6 weeks
|
|
Hydration status
Time Frame: Through study completion, average of 6 weeks
|
The primary objective of this study is to investigate the efficacy of two different oral rehydration solutions on the hydration status in healthy males via urine specific gravity analysis.
|
Through study completion, average of 6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Jeremy Townsend, PhD, Lipscomb University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2022
Primary Completion (Actual)
November 1, 2022
Study Completion (Actual)
January 1, 2023
Study Registration Dates
First Submitted
June 15, 2022
First Submitted That Met QC Criteria
June 17, 2022
First Posted (Actual)
June 23, 2022
Study Record Updates
Last Update Posted (Actual)
January 25, 2023
Last Update Submitted That Met QC Criteria
January 23, 2023
Last Verified
January 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- Pilot
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fluid Retention
-
Istanbul UniversityCompletedFluid Retention TissueTurkey
-
Nova Southeastern UniversityCompletedPerfusion; Complications | Fluid Retention TissueUnited States
-
University of ConnecticutUnited States Department of Defense; AMP Human; Park City, UTCompletedCognitive Change | Electrolyte and Fluid Balance Conditions | Fluid Retention | Heat Exposure | Fluid Loss | Hyperhydration | Sodium RetentionUnited States
-
Fujian Shengdi Pharmaceutical Co., Ltd.RecruitingPhase II Clinical Study of HRS-9057 Injection in Patients With Heart Failure-induced Fluid RetentionFluid Retention Caused by Heart FailureChina
-
Zoll Medical CorporationCompletedFluid Retention TissueUnited States
-
University of ConnecticutUnited States Department of Defense; AMP Human; Park City, UTCompletedElectrolyte and Fluid Balance Conditions | Fluid Retention | Dehydration (Physiology) | Heat Stress | Renal Injury | Sodium RetentionUnited States
-
University Hospital Inselspital, BerneCompletedBlood Loss, Surgical | Fluid RetentionSwitzerland
-
University Hospital Inselspital, BerneCompletedBlood Loss, Surgical | Fluid RetentionSwitzerland
-
Medical University of WarsawUnknownCardiac Output, Low | Body Fluid Retention | ImpedancePoland
-
Guangdong Provincial People's HospitalCompleted
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AkesoNot yet recruitingAtopic DermatitisChina
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
Chong Kun Dang PharmaceuticalUnknownHypertension | DyslipidemiasKorea, Republic of